Navigation Links
Study Suggests Way to 'Mop Up' Leukemia Cells
Date:1/8/2010

Vaccine beats back cancer left behind after treatment, researchers say,,,,

FRIDAY, Jan. 8 (HealthDay News) -- Preliminary research suggests that a vaccine could help reduce the risk of a relapse in some people who take the drug Gleevec to treat chronic myeloid leukemia.

"Should this vaccine approach prove to be successful, the ability to get patients off lifelong Gleevec therapy would be a significant advance," Dr. Hyam Levitsky, a professor of oncology, medicine and urology at the Johns Hopkins Kimmel Cancer Center in Baltimore, said in a news release from the center.

Imatinib mesylate (Gleevec) treats chronic myeloid leukemia, but can leave some cancerous cells behind. They can cause a relapse.

Researchers from the cancer center tested a vaccine on 19 people who had cancerous cells even though they'd taken Gleevec for a year. After about 72 months, the number of cancer cells had declined in 13 people. In seven, the cancer had vanished. Reported side effects of the treatment were relatively rare.

But it's not clear if the results were actually caused by the vaccine, the researchers said, because of the small number of participants and the lack of comparison with other treatments.

"We want to get rid of every last cancer cell in the body," Levitsky said, "and using cancer vaccines may be a good way to mop up residual disease."

The vaccine was made from cancer cells that were blasted with radiation to stop them from being cancerous, the researchers said.

The research, funded by the U.S. National Institutes of Health, was published in the Jan. 1 issue of Clinical Cancer Research.

More information

The U.S. National Cancer Institute has more on Gleevec.



-- Randy Dotinga



SOURCE: Johns Hopkins Kimmel Cancer Center, news release, Jan. 6, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Periodic Paralysis Study Reveals Gene Causing Disorder
2. UCLA study shows metformin is safe for patients with advanced heart failure and diabetes mellitus
3. Technology new gateway into treatment for problem alcohol users: Study
4. Few breast cancer surgeons follow quality of care standards, U-M study finds
5. Study shows serious emotional disturbances among children after Katrina
6. Study links restless leg syndrome with erectile dysfunction in older men
7. Study identifies those elderly most at risk for major depression
8. Despite Earlier Doubts, Feinstein Study Shows Fetal Transplants May Benefit Parkinson's Patients Over Age 60
9. New Study Shows That American Public is Willing to Accept Major Reforms in Medicare Program
10. Herbal Science Organization Clarifies New Ginkgo Study
11. CRN Responds to Ginkgo Biloba Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , ... May 27, 2016 , ... ... installment is bolstered by inspiring human interest stories, courtesy of leaders in the ... and tech within the industry, from leading advocates and associations—namely Jones & Bartlett ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the ... and suppliers for its inaugural Member Conference at the Paris Hotel in Las ... the operational health of America’s healthcare providers. , The conference was highlighted by ...
(Date:5/26/2016)... ... 2016 , ... The Woodlands at John Knox Village , Florida’s first ... for living and healing, celebrated its grand opening, today. The Woodlands at John Knox ... by Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... and development solutions for drugs, biologics, consumer health and global clinical supply services, ... in Korea to support the company’s continued investment and strategic growth plans in ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
(Date:5/24/2016)... -- The innovator of COMBO ... s first dual therapy stent, introduces catheters for lower ... a global company specializing in the provision of life-changing ... to treat peripheral artery disease. The JADE™ and Scoreflex™ ... lower limb and arteriovenous (AV) fistula intervention. ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse ... cathéters destinés à l,intervention portant sur les ...   OrbusNeich, entreprise mondiale spécialisée ... de changer la vie, a élargi son ...
Breaking Medicine Technology: